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Abstract  
Background 
The significant variation in the clinical behaviour of sporadic medullary thyroid carcinoma 
(sMTC) causes uncertainty when planning the management of these patients. Several tumour 
genetic and epigenetic markers have been described, but their clinical usefulness remains 
unclear. The aim of this review was to evaluate the evidence for the use of molecular genetic 
and epigenetic profiles in the risk-stratification and management of sMTC. 
 
Methods 
Medline and Embase databases were searched using the MeSH terms “medullary carcinoma”, 
“epigenetics”, “molecular genetics”, “microRNAs”; and free text terms “medullary 
carcinoma”, “sporadic medullary thyroid cancer”, “sporadic medullary thyroid carcinoma”, 
“RET”, “RAS” and “miR”. Articles containing less than ten subjects, not focussing on sMTC, 
or not reporting clinical outcomes were excluded. Risk of bias was assessed using a modified 
version of the Newcastle-Ottawa Scale.  
 
Results 
Twenty-three studies met the inclusion criteria, and key findings were summarised in themes 
according to the genetic and epigenetic markers studied. There is good evidence that somatic 
RET mutations predict higher rates of lymph node metastasis and persistent disease, and worse 
survival. There are also several good quality studies demonstrating associations between 
certain epigenetic markers such as tumour miR-183 and miR-375 expression and higher rates 
of lymph node and distant metastasis, and worse survival.  
 
Conclusions 
There is a growing body of evidence that tumour genetic and epigenetic profiles can be used to 
risk-stratify patients with sMTC. Further research should focus on the clinical applicability of 
these findings by investigating the possibility of tailoring management to an individual’s 
tumour mutation profile.  
 
1. Introduction 
 
1.1 Rationale 
 
Medullary thyroid carcinoma (MTC) is a malignant tumour of the neural crest derived 
parafollicular C cells. Due to the recent increase in incidence of papillary thyroid carcinoma, 
MTC now comprises only 1-2% of all thyroid cancers1, but accounts for a significant 
proportion of thyroid cancer morbidity and mortality. The rate of regional and distant 
metastasis at presentation is up to 35% and 13%, respectively2, and there has been no trend 
towards earlier stage at diagnosis or improved overall survival in recent decades3.  
 
Approximately 20-25% of patients have hereditary MTC (hMTC) either as part of the multiple 
endocrine neoplasia syndromes (MEN2A and MEN2B) or in isolation as familial medullary 
thyroid carcinoma (FMTC), however in the majority of cases the disease is sporadic (sMTC)4. 
Although around 7% of those with apparently sporadic MTC do indeed harbour germline 
mutations5, this group is a minority and is not included in the definition of sMTC used in this 
article. sMTC often follows an unpredictable course, with some patients suffering rapidly 
progressive and ultimately fatal disease, some surviving for many decades with incurable but 
stable disease, and others with relatively indolent disease amenable to cure following surgery.  
 
The gold standard treatment for patients with biopsy proven, node negative sMTC is total 
thyroidectomy and central compartment neck dissection (CCND)1, 6. The role of prophylactic 
lateral compartment neck dissection is less clear, with subtle differences in the guidance 
offered by the American Thyroid Association (ATA) and British Thyroid Association (BTA)1, 
6. There is also a lack of unanimity on the subject of limited surgery for small tumours, with 
the ATA suggesting that hemithyroidectomy is sufficient if the post-operative serum 
calcitonin is less than 1000pg/ml1, and the BTA using a tumour diameter of less than 5mm as 
a cut-off 6. Other authors have advocated thyroidectomy alone without central compartment 
neck dissection in patients with tumours smaller than 2cm7. 
 
These subtle but important differences suggest that there is a lack of good evidence to define 
the best approach when considering the extent of initial surgery in MTC. In reality, many 
patients receive multiple operations, either to address the lateral compartment lymph nodes 
armed with information on central compartment occult nodal metastases and post-operative 
calcitonin levels, or as a result of a conservative approach with subsequent disease recurrence 
in cervical lymph nodes.  
 
1.2 Objective 
 
The difficulty in predicting the clinical course and prognosis at the time of diagnosis makes 
management planning particularly challenging in sMTC. Currently the role of somatic genetic 
and epigenetic profiles in the management of sMTC is unknown. Their use in risk 
stratification may help to guide treatment and allow improved prognostication, as well as more 
individualised follow-up. It would allow better planning of the initial operation, for example to 
include a more aggressive neck dissection in cases with a high risk of cervical lymph node 
metastasis. Furthermore, it would rationalise inclusion criteria for clinical trials in the current 
era of personalised medicine and a rapidly increasing selection of novel anti-cancer drugs.  
The objective of this review is to systematically evaluate the current evidence for value of 
somatic molecular genetic and epigenetic markers in the risk stratification of patients with 
sMTC.   
 
 
2. Materials and methods 
 
2.1 Study design and eligibility criteria 
 
The search strategy and inclusion criteria were outlined in advance in a protocol and 
registered with the PROSPERO international prospective register of systematic reviews. The 
protocol can be accessed at https://www.crd.york.ac.uk/prospero/ (registration number: 
CRD42019131092). All studies reporting the use of genetic or epigenetic markers in risk 
stratification and prognostication of patients with sMTC were considered. Articles were 
excluded if they did not focus primarily on patients with sMTC, or contained less than 10 
subjects. Articles in languages other than English were excluded, as were articles not 
published in the last 25 years. Case reports, correspondence, commentaries and reviews were 
not eligible for inclusion.  
 
2.2 Search strategy 
 
The Cochrane library and PROSPERO international prospective register of systematic reviews 
were searched using a single search term: “medullary thyroid carcinoma” to identify relevant 
previous reviews on the topic, however none were identified. A search of Medline and Embase 
using the Ovid platform was then performed using the MeSH search terms “MEDULLARY 
CARCINOMA”, “EPIGENETICS”, “MOLECULAR GENETICS”, “MICRORNAS”; and 
free text terms “MEDULLARY CARCINOMA”, “SPORADIC MEDULLARY THYROID 
CANCER”, “SPORADIC MEDULLARY THYROID CARCIMONA”, “RET”, “RAS” and 
“miR”. Finally, a manual search of bibliographies of included studies was performed. The last 
search was performed on 3rd April 2019.  The search log and Boolean operators used are 
outlined in Appendix 1.   
 
2.3 Study selection and data extraction 
 
Titles and abstracts of identified articles were screened for inclusion independently by two 
assessors based on the criteria outlined in section 2.1. If relevance was not evident after 
reading the title and abstract then the full text was studied before making a decision. Any 
disagreement between assessors was settled by a third assessor if consensus could not be 
reached. A data capture sheet was used to record study design; number of subjects; specific 
markers investigated; outcome measures; and key findings from included articles.  
 
2.4 Data analysis 
 
Due to the variation in study design and outcome reporting, formal statistical meta-analysis 
was not possible.  Therefore, following article identification, key findings were grouped 
according to the genetic marker used and presented as a narrative synthesis.  
 
2.5 Risk of bias assessment 
 
The studies included in this review were not randomised and were not testing an intervention, 
so tools for assessing the risk of bias in clinical trials were not applicable. A modification of 
the Newcastle Ottawa scale (Appendix 2) was therefore used to estimate the risk of bias in 
included studies. 
 
3. Results 
 
3.1 Search results and study selection 
 
The initial search outlined in section 2.1 identified 1,036 articles. A manual search of 
bibliographies yielded a further 12 articles giving a total of 1,048. After screening articles for 
eligibility, and filtering for articles published in the last 25 years and with human subjects 
1,025 articles could be excluded. This left 23 articles meeting the inclusion criteria (Figure 1).   
 3.2 Characteristics of included studies 
 
The twenty-three included studies were published between 1996 and 2018, and apart from one 
randomised controlled trial8 and one prospective cohort study9, all were retrospective in 
design. They contained a combined total of 1,713 patients. Although all studies focused on the 
use of genetic and epigenetic markers in the risk stratification or prognostication of sMTC, 
there were a variety of specific markers used. The majority investigated the clinical role of 
somatic RET mutations8, 10-20, however four included somatic RAS mutations12, 13, 21, 22 and one 
focussed on somatic CDKN2C mutations23. Six studies utilised tumour miRNA expression9, 21, 
24-27, two focussed on tumour methylation levels28, 29, and one on tumour mTOR expression30. 
The general characteristics of included studies are represented in table 1. The risk of bias in 
the included studies varied significantly, with modified Newcastle Ottawa scores ranging from 
3 to 7 out of 8 (8 being highest quality). Sources of potential bias arose from non-consecutive 
patient selection and inadequate follow-up duration in most cases, although none were deemed 
unworthy of inclusion solely based on their risk of bias.    
 
3.3 Somatic RET mutations  
 
Chance heterozygous mutations in somatic tissue will be retained in the clonal progeny of the 
cell in which they occur, and can occur either as a cause or effect of cancer.  Somatic RET 
mutations are present in up to 66% of sMTC17, 20, and there is significant evidence to suggest 
that they are associated with worse outcomes. This was first demonstrated in 199620, and later 
by Elisei et al in their study of 100 patients with 10-year follow-up18. The authors found a 
correlation between somatic RET mutations and lymph node metastasis at presentation, lower 
biochemical cure rate following surgery, and worse long-term survival. Other authors have 
also demonstrated more advanced tumour stage and worse outcomes in patients with somatic 
RET mutations16, 17, and improved specificity when combining the use of somatic RET 
mutations and tumour Ki-67 expression levels15.  
 
Although there are a large number of described somatic RET mutations in sMTC, the 
commonest is the p.Met918Thr (M918T) mutation, which is also the germline mutation 
responsible for around 95% of cases of MEN2B1. The somatic M918T mutation has been 
identified in up to 68% of sMTC31. It is considered to predict the worst outcome19, and along 
with the p.Ala883Phe (A883F) mutation is associated with higher rates of lymph node 
metastasis, multifocality and persistent disease at last follow-up when compared with patients 
with other somatic RET mutations or none16. Double RET mutations have also been associated 
with worse outcomes11. A meta-analysis of 23 studies found that somatic RET mutations are 
associated with a higher rate of lymph node metastasis, distant metastasis, advanced stage at 
diagnosis, recurrence and mortality32. The M918T mutated tumour DNA can also be identified 
in peripheral blood, and there is some evidence that circulating M918T mutated DNA portends 
a worse overall survival and more accurately predicts outcome than calcitonin doubling time10.  
 
Given the established role of RET in hMTC and that almost half of sMTCs harbour somatic 
RET mutations, most efforts at novel drug development have focussed on inhibiting RET and 
RET-related pathways (Figure 2). This has resulted in the licencing of tyrosine kinase 
inhibitors (TKI) with specificity for RET, vandetanib and cabozantinib. Both drugs have been 
found to be superior to placebo in double blind randomised controlled trials in terms of 
progression free survival in populations consisting of both hMTC and sMTC8, 33. In the 
original vandetanib trial, an M918T RET mutation was identified in 142 of 298 patients with 
sMTC, and subgroup analysis revealed a higher response rate and superior progression-free 
survival in these patients8.  However, a recent meta-analysis of studies on vandetanib found 
minimal evidence of significant benefit, with no evidence of improved overall survival and a 
significant risk of side effects, which may significantly impact quality of life34. It is notable 
that the studies included in this meta-analysis consisted of patients with both hMTC and 
sMTC, and subgroup analysis according to somatic mutational profile was not possible. It is 
conceivable that stratification by genetic profile may have altered the results given the 
evidence of improved response rates of M918T RET sMTC.   
 
More recently, two selective RET inhibitors have been developed which are still being 
evaluated in clinical trials. LOXO-292 is under investigation in a phase 2 study, however 
preliminary results have demonstrated preclinical activity against various RET alterations. 
Furthermore, its use in a patient with advanced sMTC with a confirmed somatic RET M918T 
mutation resulted in tumour regression, a drop in serum calcitonin and symptom 
improvement35. The second drug, BLU-667 is also a selective RET inhibitor still in phase 2 
trials, however once again preliminary data has shown a good response in a patient with sMTC 
and multiple RET mutations36. Clearly it is too early to draw conclusions on the efficacy of 
these novel drugs or the relative effects in patients with different RET mutations, however 
these preliminary results are promising. 
 
3.4 Somatic RAS mutations  
 
Somatic RAS mutations are present in 30% of all human cancers37. In sMTC, somatic RAS 
mutations have been identified in up to 81% of RET negative tumours, and almost never co-
exist in RET mutated tumours12, 13, 22, 30.  In contrast to follicular cell thyroid cancers, MTC 
tends to harbour HRAS mutations most commonly and NRAS mutations rarely, with the 
commonest being HRAS p.Gln61Arg38.  
 
The clinical significance of somatic RAS mutations has been less thoroughly investigated, and 
although some data suggests that they predict a more favourable outcome compared to somatic 
RET mutations in sMTC, none of the studies identified in this review were able to demonstrate 
this with statistical significance12, 13, 22. Moura et al divided their 2011 cohort of sMTC patients 
into four groups depending on the presence of high-risk somatic RET mutations (M918T and 
A883F), other RET mutations, RAS mutations and no mutations38. They found that tumours 
with somatic RAS mutations behaved less aggressively than those with high risk RET 
mutations, but more aggressively than those with other RET mutations. Although Cavedon et 
al were unable to identify a significant association between somatic RAS mutation and 
favourable outcome; they did find that tumour miR-224 under-expression correlated with 
shorter overall survival, and that somatic RAS mutations correlated with miR-224 over-
expression21. They therefore concluded that somatic RAS mutations in sMTC predict a less 
aggressive phenotype.  
 
3.5 Other genetic pathways 
 
In up to 45% of sMTC, no somatic RET or RAS mutation is identified. This has led some 
authors to investigate the role of other related pathways, as well as epigenetic regulation of 
gene expression. In general, the quest for novel genes regulating tumorigenesis in MTC has 
focused on oncogenes in other cancer types, and been relatively fruitless39. However, exome 
sequencing on a patient with MTC and no identifiable RET mutation has identified a germline 
frameshift c.948delT mutation in the ESR2 gene40. This mutation was also present in 3 family 
members with C-cell hyperplasia, and immunohistochemical studies confirmed its effect being 
the loss of ERβ and overexpression of RET. This finding of indirect up-regulation of RET 
expression leading to MTC, provides an interesting insight into alternate pathways for 
developing MTC, although it has yet to be replicated by other researchers, and its role in 
sMTC is as yet unknown41.  
 
The CDKN gene family, encoding cyclin-dependent kinase inhibitors has attracted some 
interest in the setting of MTC. These genes play a vital role in cell cycle control and have been 
implicated in many cancers, suggesting a tumour suppressor role42. Somatic copy number loss 
in the CDKN2C gene has been identified in 19% of a cohort of 62 sMTC cases, and associated 
with higher rates of distant metastasis and worse overall survival23. Genotyping of the CDKN 
genes revealed a significant association between single nucleotide polymorphisms (SNPs) in 
the CDKN1B and CDKN2A genes and susceptibility to sMTC43. Both of these genes encode 
cyclin dependent kinases with cell cycle control roles, with the latter being an important 
stabiliser of the p53 tumour suppressor protein.  More recently, fluorescence in situ 
hybridisation has been used to identify loss of heterozygosity in CDKN2C and CDKN2D in 
formalin fixed paraffin embedded MTC samples, raising the possibility of a clinically useful 
prognostic marker42.  
 
Based on evidence that the CDK/RB pathway may be an alternative target for treatment of 
MTC, in vitro research has demonstrated that dinaciclib (a CDK1/2/5/9 inhibitor) reduced 
mRNA levels of CD7 and RET in MTC cells44. The effect was synergistic when dinaciclib was 
used in combination with a TKI, and the authors postulate the possibility of its use to improve 
therapeutic RET targeting in MTC.  
 
The mTOR pathway is activated in both hMTC and sMTC45, and there is some evidence that 
high mTOR activity as measured by tumour p-S6 expression is associated with more invasive 
sMTC and higher rates of lymph node metastasis30. Inhibitors of the mTOR pathway have 
therefore been investigated in advanced MTC, with a phase II trial of Everolimus showing 
some benefit46.  
 
3.6 Epigenetic markers in sMTC 
 
Epigenetics can be defined as stably inherited modulations in the expression of genes without 
altering DNA sequence47.  The epigenetic control of gene expression is known to influence 
oncogenesis and tumour behaviour in many cancer types, mainly via aberrations in the histone 
acetylation and methylation pathways48. Although there has been little research on methylation 
profiles in MTC, a recent study by Ceolin et al found that global DNA methylation levels in 
peripheral blood leucocytes were higher in sMTC patients than hMTC patients28. The authors 
were unable to identify any correlation between DNA methylation levels and tumour 
characteristics or clinical outcome.  
 
A significant increase in gene expression of the histone methyltransferases EZH2 and SMYD3 
has been found in samples from MTC patients with local and distant metastasis, irrespective of 
germline and somatic RET and RAS mutation status49. This adds further weight to the 
suggestion that MTC tumour progression may be controlled by epigenetic factors independent 
of RET and RAS pathways.  Telomerase activity is controlled by the TERT gene, which is 
usually suppressed in normal tissue, but activated in many human cancers to allow cell 
proliferation. Although TERT gene promoter mutations have not been identified in MTC50, 
TERT copy number gain has been demonstrated in a subset of patients with sMTC, as well as 
increased methylation of the TERT promoter region in both hMTC and sMTC patients29. The 
same group found a statistically significant association between higher TERT methylation 
index, and poorer disease-free and overall survival. They postulated that the methylation of the 
TERT promoter region stimulates TERT expression and telomerase activation thereby 
contributing to more aggressive disease.  
 
MicroRNAs (miRNAs) are molecules capable of down-regulating gene expression, and have 
thus been implicated in both carcinogenesis via down-regulation of tumour suppression genes, 
and tumour progression. Overexpression of miR-183 and miR-375 have been identified in 
sMTC compared with hMTC, and are associated with increased rates of lateral cervical lymph 
node metastases, distant metastases and mortality27. Other investigators have also identified a 
positive association between miR-375 levels and tumour stage at diagnosis, lymph node 
metastasis, calcitonin level at diagnosis and disease progression, independent of RET and RAS 
status25.  
 
miR-183 has been found to down-regulate the expression of the pro-apoptotic gene PDCD451, 
and has been implicated in the oncogenesis of other cancers52, 53. Down regulation of PDCD4 
in association with overexpression of miR-29 is a possible carcinogenic factor in both sMTC 
and hMTC54. More recently, the expression of six miRNAs was measured in a cohort of 54 
sMTCs, and miR-183 was again found to correlate strongly with lymph node metastasis. In 
addition to miR-183, miR-21 expression was also found to correlate with lymph node 
metastasis as well as tumour size, baseline serum calcitonin and T3/T4 tumours at 
presentation24. The authors postulated that routinely testing this marker could guide surgeons 
in the extent of cervical lymph node dissection. Table 2 summarises the prognostic effects of 
various somatic genetic and epigenetic changes.  
 
The recent interest in epigenetic factors in sMTC has led some to investigate the feasibility of 
targeting epigenetic regulators with the aim of developing novel therapeutic agents. As early 
as 2005, in vitro experiments revealed the efficacy of histone deacetylase inhibitors in 
supressing proliferation and inducing apoptosis in thyroid cancer cell lines55. miRNA therapy 
has now been trialled in other forms of human cancer, with the first molecule to be studied 
being MRX34, an miR-34a mimic which supresses oncogenes targeted by miR-34a56. Initial 
phase I studies showed promising anti-tumour efficacy, but significant adverse effect profiles. 
Interestingly, miR-34a expression has been found to be raised in MTC, rather than reduced as 
in other cancers57. Furthermore, Lassalle et al have demonstrated in vitro that overexpression 
of miR-375, one of the most studied miRNAs in MTC, results in improved efficacy of 
vandetanib on cancer cells58.  
 
4. Discussion 
 
4.1 Summary of key findings 
 
This review demonstrates the emerging complexity of the molecular genetic and epigenetic 
landscape in sMTC. There is now a significant body of evidence supporting the use of various 
genetic and epigenetic markers in risk stratification of patients with sMTC, however few 
authors have used this information to personalise management plans. Currently the clinical 
stage and serum calcitonin levels dictate the extent of initial and subsequent surgery in these 
patients, although with increasing availability of genetic profiling of tumours, the 
incorporation of tumour-specific genetic and epigenetic markers into the decision making 
process is becoming more feasible.  
 
There is substantial evidence that somatic RET mutations predict more aggressive tumour 
behaviour and a worse outcome, however it is not clear whether these mutations actually drive 
tumorigenesis in sMTC. Some patients demonstrate heterogeneity of RET mutation in cell 
subpopulations both within different areas of the same primary tumour, and within different 
metastases from the same patient7, 59. This suggests that the mutation is not an early event in 
tumorigenesis, and incidentally may also explain the wide variation in reported frequency, as 
its detection depends on which part of a tumour is tested. Furthermore, the presence of somatic 
RET mutations is not unique to MTC and may represent a marker of poor prognosis in many 
cancers, with various mutations, including M918T, having been identified in breast, lung and 
liver cancers, correlating with advanced disease stage and poor survival60-62. This suggests that 
the somatic RET mutation may play more of a role in tumour progression than tumorigenesis.  
 
The role of somatic RAS mutations in predicting clinical course is still not well understood, 
and the findings of some authors that their presence predicts more favourable outcomes may 
simply reflect the fact that these tumours almost always lack somatic RET mutations. Up to 
45% of sMTC express neither RET or RAS somatic mutations, which suggests a role for other 
mechanisms. The field of epigenetics is growing rapidly, and there is increasing evidence for a 
role for several epigenetic markers in risk stratification of sMTC. The most promising of these 
are miR-21, miR-183 and miR-375, which have been shown by several authors to be 
associated with increased risk of lymph node metastasis in sMTC24, 25, 27. These markers could 
complement serum calcitonin levels and stage of disease in helping to guide decision-making 
when considering the need for lateral compartment neck dissections in the absence of clinical 
or radiological evidence of nodal metastases.   
 
A significant barrier to the use of these tumour specific markers in risk stratification and 
management planning is the fact that they are frequently not available at the time of initial 
diagnosis as their detection relies upon analysis of excised tumour tissue. The work of Cote et 
al on the detection of circulating RET-mutated tumour DNA10, and Romeo et al on circulating 
miR-3759 is therefore particularly interesting. In addition to their potential use in 
prognosticating and planning surgical management, genetic and epigenetic characteristics of 
sMTC tumours may also be valuable in predicting response to novel therapies and developing 
new therapeutic agents. The improved response rate to vandetanib amongst patients with 
somatic RET M918T mutations demonstrated by Wells et al, and the suggestion by Lassalle et 
al that tumour miR-375 overexpression increases susceptibility to vandetanib raise the 
possibility of using somatic mutation profiles to guide medical therapy8, 58.   
 
4.2 Limitations 
 
The field of molecular genetics in MTC is rapidly evolving and there is substantial evidence in 
the form of retrospective studies to support associations between various tumour genetic and 
epigenetic markers and clinico-pathological features. However, the number of studies is still 
relatively limited, and with each using different molecular genetic characteristics and slightly 
different outcome measures, comparison of findings is difficult. Furthermore, there is a dearth 
of prospective evidence on the use of these markers to inform management of patients with 
sMTC. The majority of research to date has focussed on somatic RET mutations, and whilst 
the evidence for their role in predicting tumour behaviour is strong, it is clear that other 
molecular genetic mechanisms play a role. Further research is required to confidently base 
management decisions on these genetic and epigenetic characteristics.   
 
4.3 Conclusions 
 
Currently clinical stage and calcitonin levels dictate the extent of initial and subsequent 
surgery for sMTC, with novel therapies being reserved for local or distant disease progression. 
The evidence presented in this review suggests that somatic RET mutations and tumour 
overexpression of certain miRNAs may predict aggressive tumour behaviour and lymph node 
metastasis. There appears therefore to be scope to improve risk stratification in sMTC. This 
could allow for more individualised decision-making, with the extent of surgery being tailored 
to patients.  Due to the rarity of these cancers, and as analysis of somatic mutations and 
epigenetic expression is not routinely analysed in most centres, a subspecialist or even 
nationalised approach to such cases may be warranted. Further research should aim to further 
clarify molecular genetic and epigenetic drivers of sMTC in order to provide more accurate 
prognostic information, inform management strategies and provide potential targets for novel 
therapeutic agents.  
 
References 	1. Wells	Jr	SA,	Asa	SL,	Dralle	H,	Elisei	R,	Evans	DB,	Gagel	RF,	Lee	N,	Machens	A,	Moley	JF,	Pacini	F,	Raue	F.	Revised	American	Thyroid	Association	guidelines	for	the	management	of	medullary	thyroid	carcinoma:	the	American	Thyroid	Association	Guidelines	Task	Force	on	medullary	thyroid	carcinoma.	Thyroid.	2015	Jun	1;25(6):567-610.	2. Roman	S,	Lin	R,	Sosa	JA.	Prognosis	of	medullary	thyroid	carcinoma:	demographic,	clinical,	and	pathologic	predictors	of	survival	in	1252	cases.	Cancer:	Interdisciplinary	International	Journal	of	the	American	Cancer	Society.	2006	Nov	1;107(9):2134-42.	
3. Kebebew	E,	Greenspan	FS,	Clark	OH,	Woeber	KA,	Grunwell	J.	Extent	of	disease	and	practice	patterns	for	medullary	thyroid	cancer.	Journal	of	the	American	College	of	Surgeons.	2005	Jun	1;200(6):890-6.	4. Pelizzo	MR,	Boschin	IM,	Bernante	P,	Toniato	A,	Piotto	A,	Pagetta	C,	Nibale	O,	Rampin	L,	Muzzio	PC,	Rubello	D.	Natural	history,	diagnosis,	treatment	and	outcome	of	medullary	thyroid	cancer:	37	years	experience	on	157	patients.	European	Journal	of	Surgical	Oncology	(EJSO).	2007	May	1;33(4):493-7.	5. Romei	C,	Cosci	B,	Renzini	G,	Bottici	V,	Molinaro	E,	Agate	L,	Passannanti	P,	Viola	D,	Biagini	A,	Basolo	F,	Ugolini	C.	RET	genetic	screening	of	sporadic	medullary	thyroid	cancer	(MTC)	allows	the	preclinical	diagnosis	of	unsuspected	gene	carriers	and	the	identification	of	a	relevant	percentage	of	hidden	familial	MTC	(FMTC).	Clinical	endocrinology.	2011	Feb;74(2):241-7.	6. Perros	P,	Boelaert	K,	Colley	S,	Evans	C,	Evans	RM,	Gerrard	BA	G,	Gilbert	J,	Harrison	B,	Johnson	SJ,	Giles	TE,	Moss	L.	Guidelines	for	the	management	of	thyroid	cancer.	Clinical	endocrinology.	2014	Jul;81:1-22.	7. Esfandiari	NH,	Hughes	DT,	Yin	H,	Banerjee	M,	Haymart	MR.	The	effect	of	extent	of	surgery	and	number	of	lymph	node	metastases	on	overall	survival	in	patients	with	medullary	thyroid	cancer.	The	Journal	of	Clinical	Endocrinology	&	Metabolism.	2014	Feb	1;99(2):448-54.	8. Wells	Jr	SA,	Robinson	BG,	Gagel	RF,	Dralle	H,	Fagin	JA,	Santoro	M,	Baudin	E,	Elisei	R,	Jarzab	B,	Vasselli	JR,	Read	J.	Vandetanib	in	patients	with	locally	advanced	or	metastatic	medullary	thyroid	cancer:	a	randomized,	double-blind	phase	III	trial.	Journal	of	clinical	oncology.	2012	Jan	10;30(2):134.	9. Romeo	P,	Colombo	C,	Granata	R,	Calareso	G,	Gualeni	AV,	Dugo	M,	De	Cecco	L,	Rizzetti	MG,	Zanframundo	A,	Aiello	A,	Carcangiu	ML.	Circulating	miR-375	as	a	novel	prognostic	marker	for	metastatic	medullary	thyroid	cancer	patients.	Endocrine-related	cancer.	2018	Mar	1;25(3):217-31.		
10. Cote	GJ,	Evers	C,	Hu	MI,	Grubbs	EG,	Williams	MD,	Hai	T,	Duose	DY,	Houston	MR,	Bui	JH,	Mehrotra	M,	Waguespack	SG.	Prognostic	significance	of	circulating	RET	M918T	mutated	tumor	DNA	in	patients	with	advanced	medullary	thyroid	carcinoma.	The	Journal	of	Clinical	Endocrinology	&	Metabolism.	2017	Jul	20;102(9):3591-9.	11. Romei	C,	Casella	F,	Tacito	A,	Bottici	V,	Valerio	L,	Viola	D,	Cappagli	V,	Matrone	A,	Ciampi	R,	Piaggi	P,	Ugolini	C.	New	insights	in	the	molecular	signature	of	advanced	medullary	thyroid	cancer:	evidence	of	a	bad	outcome	of	cases	with	double	RET	mutations.	Journal	of	medical	genetics.	2016	Nov	1;53(11):729-34.	12. Simbolo	M,	Mian	C,	Barollo	S,	Fassan	M,	Mafficini	A,	Neves	D,	Scardoni	M,	Pennelli	G,	Rugge	M,	Pelizzo	MR,	Cavedon	E.	High-throughput	mutation	profiling	improves	diagnostic	stratification	of	sporadic	medullary	thyroid	carcinomas.	Virchows	archiv.	2014	Jul	1;465(1):73-8.	13. Ciampi	R,	Mian	C,	Fugazzola	L,	Cosci	B,	Romei	C,	Barollo	S,	Cirello	V,	Bottici	V,	Marconcini	G,	Rosa	PM,	Borrello	MG.	Evidence	of	a	low	prevalence	of	RAS	mutations	in	a	large	medullary	thyroid	cancer	series.	Thyroid.	2013	Jan	1;23(1):50-7.	14. Romei	C,	Ugolini	C,	Cosci	B,	Torregrossa	L,	Vivaldi	A,	Ciampi	R,	Tacito	A,	Basolo	F,	Materazzi	G,	Miccoli	P,	Vitti	P.	Low	prevalence	of	the	somatic	M918T	RET	mutation	in	micro-medullary	thyroid	cancer.	Thyroid.	2012	May	1;22(5):476-81.	15. Mian	C,	Pennelli	G,	Barollo	S,	Cavedon	E,	Nacamulli	D,	Vianello	F,	Negro	I,	Pozza	G,	Boschin	IM,	Pelizzo	MR,	Rugge	M.	Combined	RET	and	Ki-67	assessment	in	sporadic	medullary	thyroid	carcinoma:	a	useful	tool	for	patient	risk	stratification.	European	journal	of	endocrinology.	2011	Jun	1;164(6):971-6.	16. Moura	MM,	Cavaco	BM,	Pinto	AE,	Domingues	R,	Santos	JR,	Cid	MO,	Bugalho	MJ,	Leite	V.	Correlation	of	RET	somatic	mutations	with	clinicopathological	features	in	
sporadic	medullary	thyroid	carcinomas.	British	journal	of	cancer.	2009	Jun;100(11):1777.	17. Dvorakova	S,	Vaclavikova	E,	Sykorova	V,	Vcelak	J,	Novak	Z,	Duskova	J,	Ryska	A,	Laco	J,	Cap	J,	Kodetova	D,	Kodet	R.	Somatic	mutations	in	the	RET	proto-oncogene	in	sporadic	medullary	thyroid	carcinomas.	Molecular	and	cellular	endocrinology.	2008	Mar	12;284(1-2):21-7.	18. Elisei	R,	Cosci	B,	Romei	C,	Bottici	V,	Renzini	G,	Molinaro	E,	Agate	L,	Vivaldi	A,	Faviana	P,	Basolo	F,	Miccoli	P.	Prognostic	significance	of	somatic	RET	oncogene	mutations	in	sporadic	medullary	thyroid	cancer:	a	10-year	follow-up	study.	The	Journal	of	Clinical	Endocrinology	&	Metabolism.	2008	Mar	1;93(3):682-7.	19. Schilling	T,	Bürck	J,	Sinn	HP,	Clemens	A,	Otto	HF,	Höppner	W,	Herfarth	C,	Ziegler	R,	Schwab	M,	Raue	F.	Prognostic	value	of	codon	918	(ATG→	ACG)	RET	proto-oncogene	mutations	in	sporadic	medullary	thyroid	carcinoma.	International	journal	of	cancer.	2001	Jan	20;95(1):62-6.	20. Romei	C,	Elisei	R,	Pinchera	A,	Ceccherini	I,	Molinaro	E,	Mancusi	FR,	Martino	E,	Romeo	G,	Pacini	F.	Somatic	mutations	of	the	RET	protooncogene	in	sporadic	medullary	thyroid	carcinoma	are	not	restricted	to	exon	16	and	are	associated	with	tumor	recurrence.	The	Journal	of	Clinical	Endocrinology	&	Metabolism.	1996	Apr	1;81(4):1619-22.	21. Cavedon	E,	Barollo	S,	Bertazza	L,	Pennelli	G,	Galuppini	F,	Watutantrige-Fernando	S,	Censi	S,	Iacobone	M,	Benna	C,	Vianello	F,	Zovato	S.	Prognostic	impact	of	miR-224	and	RAS	mutations	in	medullary	thyroid	carcinoma.	International	journal	of	endocrinology.	2017;2017:4915736	22. Moura	MM,	Cavaco	BM,	Pinto	AE,	Leite	V.	High	prevalence	of	RAS	mutations	in	RET-negative	sporadic	medullary	thyroid	carcinomas.	The	Journal	of	Clinical	Endocrinology	&	Metabolism.	2011	May	1;96(5):E863-8.	
23. Grubbs	EG,	Williams	MD,	Scheet	P,	Vattathil	S,	Perrier	ND,	Lee	JE,	Gagel	RF,	Hai	T,	Feng	L,	Cabanillas	ME,	Cote	GJ.	Role	of	CDKN2C	copy	number	in	sporadic	medullary	thyroid	carcinoma.	Thyroid.	2016	Nov	1;26(11):1553-62.	24. Aubert	S,	Berdelou	A,	Gnemmi	V,	Behal	H,	Caiazzo	R,	D’herbomez	M,	Pigny	P,	Wemeau	JL,	Carnaille	B,	Renaud	F,	Bouchindhomme	B.	Large	sporadic	thyroid	medullary	carcinomas:	predictive	factors	for	lymph	node	involvement.	Virchows	Archiv.	2018	Mar	1;472(3):461-8.	25. Galuppini	F,	Bertazza	L,	Barollo	S,	Cavedon	E,	Rugge	M,	Guzzardo	V,	Sacchi	D,	Watutantrige-Fernando	S,	Vianello	F,	Mian	C,	Pennelli	G.	MiR-375	and	YAP1	expression	profiling	in	medullary	thyroid	carcinoma	and	their	correlation	with	clinical–pathological	features	and	outcome.	Virchows	Archiv.	2017	Nov	1;471(5):651-8.	26. Mian	C,	Pennelli	G,	Fassan	M,	Balistreri	M,	Barollo	S,	Cavedon	E,	Galuppini	F,	Pizzi	M,	Vianello	F,	Pelizzo	MR,	Girelli	ME.	MicroRNA	profiles	in	familial	and	sporadic	medullary	thyroid	carcinoma:	preliminary	relationships	with	RET	status	and	outcome.	Thyroid.	2012	Sep	1;22(9):890-6.	27. Abraham	D,	Jackson	NE,	Gundara	JS,	Zhao	J,	Gill	AJ,	Delbridge	L,	Robinson	B,	Sidhu	S.	MicroRNA	profiling	of	sporadic	and	hereditary	medullary	thyroid	cancer	identifies	predictors	of	nodal	metastasis,	prognosis	and	potential	therapeutic	targets.	Clinical	cancer	research.	2011	May	27:clincanres-0242.	28. Ceolin	L,	Goularte	AP,	Ferreira	CV,	Romitti	M,	Maia	AL.	Global	DNA	methylation	profile	in	medullary	thyroid	cancer	patients.	Experimental	and	Molecular	Pathology.	2018	Aug;	105(1):	110-114.	29. Wang	N,	Kjellin	H,	Sofiadis	A,	Fotouhi	O,	Juhlin	CC,	Bäckdahl	M,	Zedenius	J,	Xu	D,	Lehtiö	J,	Larsson	C.	Genetic	and	epigenetic	background	and	protein	expression	profiles	in	relation	to	telomerase	activation	in	medullary	thyroid	carcinoma.	Oncotarget.	2016	Apr	19;7(16):21332.	
30. Lyra	J,	Vinagre	J,	Batista	R,	Pinto	V,	Prazeres	H,	Rodrigues	F,	Eloy	C,	Sobrinho-Simões	M,	Soares	P.	mTOR	activation	in	medullary	thyroid	carcinoma	with	RAS	mutation.	European	journal	of	endocrinology.	2014	Nov	1;171(5):633-40.	31. Marsh	DJ,	Learoyd	DL,	Andrew	SD,	Krishnan	L,	Pojer	R,	Richardson	AL,	Delbridge	L,	Eng	C,	Robinson	BG.	Somatic	mutations	in	the	RET	proto-oncogene	in	sporadic	medullary	thyroid	carcinoma.	Clinical	endocrinology.	1996	Mar;44(3):249-57.	32. Vuong	HG,	Odate	T,	Ngo	HT,	Pham	TQ,	Tran	TT,	Mochizuki	K,	Nakazawa	T,	Katoh	R,	Kondo	T.	Clinical	significance	of	RET	and	RAS	mutations	in	sporadic	medullary	thyroid	cancer-a	meta-analysis.	Endocrine-related	cancer.	2018	Jun;25(6):633-41.	33. Elisei	R,	Schlumberger	MJ,	Müller	SP,	Schöffski	P,	Brose	MS,	Shah	MH,	Licitra	L,	Jarzab	B,	Medvedev	V,	Kreissl	MC,	Niederle	B.	Cabozantinib	in	progressive	medullary	thyroid	cancer.	Journal	of	clinical	oncology.	2013	Oct	10;31(29):3639.	34. Trimboli	P,	Castellana	M,	Virili	C,	Giorgino	F,	Giovanella	L.	Efficacy	of	Vandetanib	in	Treating	Locally	Advanced	or	Metastatic	Medullary	Thyroid	Carcinoma	According	to	RECIST	Criteria:	A	Systematic	Review	and	Meta-Analysis.	Frontiers	in	endocrinology.	2018;9.	35. Subbiah	V,	Velcheti	V,	Tuch	BB,	Ebata	K,	Busaidy	NL,	Cabanillas	ME,	Wirth	LJ,	Stock	S,	Smith	S,	Lauriault	V,	Corsi-Travali	S.	Selective	RET	kinase	inhibition	for	patients	with	RET-altered	cancers.	Annals	of	Oncology.	2018	Apr	18;29(8):1869-76.	36. Subbiah	V,	Gainor	JF,	Rahal	R,	Brubaker	JD,	Kim	JL,	Maynard	M,	Hu	W,	Cao	Q,	Sheets	MP,	Wilson	D,	Wilson	KJ.	Precision	targeted	therapy	with	BLU-667	for	RET-driven	cancers.	Cancer	discovery.	2018	Jul	1;8(7):836-49.	37. Forbes	SA,	Bindal	N,	Bamford	S,	Cole	C,	Kok	CY,	Beare	D,	Jia	M,	Shepherd	R,	Leung	K,	Menzies	A,	Teague	JW.	COSMIC:	mining	complete	cancer	genomes	in	the	
Catalogue	of	Somatic	Mutations	in	Cancer.	Nucleic	acids	research.	2010	Oct	15;39(suppl_1):D945-50.	38. Moura	MM,	Cavaco	BM,	Leite	V.	RAS	proto-oncogene	in	medullary	thyroid	carcinoma.	Endocrine-related	cancer.	2015	Oct	1;22(5):R235-52.	39. Cerrato	A,	De	Falco	V,	Santoro	M.	Molecular	genetics	of	medullary	thyroid	carcinoma:	the	quest	for	novel	therapeutic	targets.	Journal	of	molecular	endocrinology.	2009	Oct	1;43(4):143-55.	40. Smith	J,	Read	ML,	Hoffman	J,	Brown	R,	Bradshaw	B,	Campbell	C,	Cole	T,	Navas	JD,	Eatock	F,	Gundara	JS,	Lian	E	et	al.	Germline	ESR2	mutation	predisposes	to	medullary	thyroid	carcinoma	and	causes	up-regulation	of	RET	expression.	Human	molecular	genetics.	2016	Mar	3;25(9):1836-45.	41. Ruiz-Ferrer	M,	Fernández	RM,	Navarro	E,	Antiñolo	G,	Borrego	S.	ESR2	Gene	and	Medullary	Thyroid	Carcinoma.	Thyroid.	2017	Nov	1;27(11):1456-7.	42. El	Naofal	M,	Kim	A,	Yon	HY,	Baity	M,	Ming	Z,	Bui-Griffith	J,	Tang	Z,	Robinson	M,	Grubbs	EG,	Cote	GJ,	Hu	P.	Role	of	CDKN2C	Fluorescence	In	Situ	Hybridization	in	the	Management	of	Medullary	Thyroid	Carcinoma.	Annals	of	Clinical	&	Laboratory	Science.	2017	Sep	1;47(5):523-8.	43. Barbieri	RB,	Bufalo	NE,	Secolin	R,	Assumpcao	LV,	Maciel	RM,	Cerutti	JM,	Ward	LS.	Polymorphisms	of	cell	cycle	control	genes	influence	the	development	of	sporadic	medullary	thyroid	carcinoma.	European	journal	of	endocrinology.	2014	Dec	1;171(6):761-7.	44. Valenciaga	A,	Saji	M,	Yu	L,	Zhang	X,	Bumrah	C,	Yilmaz	AS,	Knippler	CM,	Miles	W,	Giordano	TJ,	Cote	GJ,	Ringel	MD.	Transcriptional	targeting	of	oncogene	addiction	in	medullary	thyroid	cancer.	JCI	insight.	2018	Aug	23;3(16).	45. Tamburrino	A,	Molinolo	AA,	Salerno	P,	Chernock	RD,	Raffeld	M,	Xi	L,	Gutkind	JS,	Moley	JF,	Wells	SA,	Santoro	M.	Activation	of	the	mTOR	pathway	in	primary	
medullary	thyroid	carcinoma	and	lymph	node	metastases.	Clinical	cancer	research.	2012	Jul	1;18(13):3532-40.	46. Schneider	TC,	De	Wit	D,	Links	TP,	van	Erp	NP,	van	der	Hoeven	JJ,	Gelderblom	H,	van	Wezel	T,	Van	Eijk	R,	Morreau	H,	Guchelaar	HJ,	Kapiteijn	E.	Beneficial	effects	of	the	mTOR	inhibitor	everolimus	in	patients	with	advanced	medullary	thyroid	carcinoma:	subgroup	results	of	a	phase	II	trial.	International	journal	of	endocrinology.	2015;2015.	47. Peschansky	VJ,	Wahlestedt	C.	Non-coding	RNAs	as	direct	and	indirect	modulators	of	epigenetic	regulation.	Epigenetics.	2014	Jan	1;9(1):3-12.	48. Dawson	MA,	Kouzarides	T.	Cancer	epigenetics:	from	mechanism	to	therapy.	Cell.	2012	Jul	6;150(1):12-27.	49. Sponziello	M,	Durante	C,	Boichard	A,	Dima	M,	Puppin	C,	Verrienti	A,	Tamburrano	G,	Di	Rocco	G,	Redler	A,	Lacroix	L,	Bidart	JM.	Epigenetic-related	gene	expression	profile	in	medullary	thyroid	cancer	revealed	the	overexpression	of	the	histone	methyltransferases	EZH2	and	SMYD3	in	aggressive	tumours.	Molecular	and	cellular	endocrinology.	2014	Jul	5;392(1-2):8-13.	50. Liu	T,	Wang	N,	Cao	J,	Sofiadis	A,	Dinets	A,	Zedenius	J,	Larsson	C,	Xu	D.	The	age-and	shorter	telomere-dependent	TERT	promoter	mutation	in	follicular	thyroid	cell-derived	carcinomas.	Oncogene.	2014	Oct;33(42):4978.	51. Li	J,	Fu	H,	Xu	C,	Tie	Y,	Xing	R,	Zhu	J,	Qin	Y,	Sun	Z,	Zheng	X.	miR-183	inhibits	TGF-β1-induced	apoptosis	by	downregulation	of	PDCD4	expression	in	human	hepatocellular	carcinoma	cells.	BMC	cancer.	2010	Dec;10(1):354.	52. Lin	WM,	Baker	AC,	Beroukhim	R,	Winckler	W,	Feng	W,	Marmion	JM,	Laine	E,	Greulich	H,	Tseng	H,	Gates	C,	Hodi	FS.	Modeling	genomic	diversity	and	tumor	dependency	in	malignant	melanoma.	Cancer	research.	2008	Feb	1;68(3):664-73.	
53. Motoyama	K,	Inoue	H,	Takatsuno	Y,	Tanaka	F,	Mimori	K,	Uetake	H,	Sugihara	K,	Mori	M.	Over-and	under-expressed	microRNAs	in	human	colorectal	cancer.	International	journal	of	oncology.	2009	Apr	1;34(4):1069-75.	54. Pennelli	G,	Galuppini	F,	Barollo	S,	Cavedon	E,	Bertazza	L,	Fassan	M,	Guzzardo	V,	Pelizzo	MR,	Rugge	M,	Mian	C.	The	PDCD4/miR-21	pathway	in	medullary	thyroid	carcinoma.	Human	pathology.	2015	Jan	1;46(1):50-7.	55. Mitsiades	CS,	Poulaki	V,	McMullan	C,	Negri	J,	Fanourakis	G,	Goudopoulou	A,	Richon	VM,	Marks	PA,	Mitsiades	N.	Novel	histone	deacetylase	inhibitors	in	the	treatment	of	thyroid	cancer.	Clinical	Cancer	Research.	2005	May	15;11(10):3958-65.	56. Beg	MS,	Brenner	AJ,	Sachdev	J,	Borad	M,	Kang	YK,	Stoudemire	J,	Smith	S,	Bader	AG,	Kim	S,	Hong	DS.	Phase	I	study	of	MRX34,	a	liposomal	miR-34a	mimic,	administered	twice	weekly	in	patients	with	advanced	solid	tumors.	Investigational	new	drugs.	2017	Apr	1;35(2):180-8.	57. Shabani	N,	Razaviyan	J,	Paryan	M,	Tavangar	SM,	Azizi	F,	Mohammadi-Yeganeh	S,	Hedayati	M.	Evaluation	of	miRNAs	expression	in	medullary	thyroid	carcinoma	tissue	samples:	miR-34a	and	miR-144	as	promising	overexpressed	markers	in	MTC.	Human	pathology.	2018	Jun	6.	58. Lassalle	S,	Zangari	J,	Popa	A,	Ilie	M,	Hofman	V,	Long	E,	Patey	M,	Tissier	F,	Belleannee	G,	Trouette	H,	Catargi	B.	MicroRNA-375/SEC23A	as	biomarkers	of	the	in	vitro	efficacy	of	vandetanib.	Oncotarget.	2016	May	24;7(21):30461.	59. Eng	C,	Mulligan	LM,	Healey	CS,	Houghton	C,	Frilling	A,	Raue	F,	Thomas	GA,	Ponder	BA.	Heterogeneous	mutation	of	the	RET	proto-oncogene	in	subpopulations	of	medullary	thyroid	carcinoma.	Cancer	research.	1996	May	1;56(9):2167-70.	60. Griseri	P,	Garrone	O,	Sardo	AL,	Monteverde	M,	Rusmini	M,	Tonissi	F,	Merlano	M,	Bruzzi	P,	Nigro	CL,	Ceccherini	I.	Genetic	and	epigenetic	factors	affect	RET	gene	
expression	in	breast	cancer	cell	lines	and	influence	survival	in	patients.	Oncotarget.	2016	May	3;7(18):26465.	61. Dabir	S,	Babakoohi	S,	Kluge	A,	Morrow	JJ,	Kresak	A,	Yang	M,	MacPherson	D,	Wildey	G,	Dowlati	A.	RET	mutation	and	expression	in	small-cell	lung	cancer.	Journal	of	Thoracic	Oncology.	2014	Sep	1;9(9):1316-23.	62. Ye	S,	Zhao	XY,	Hu	XG,	Li	T,	Xu	QR,	Yang	HM,	Huang	DS,	Yang	L.	TP53	and	RET	may	serve	as	biomarkers	of	prognostic	evaluation	and	targeted	therapy	in	hepatocellular	carcinoma.	Oncology	reports.	2017	Apr	1;37(4):2215-26.	
 
 
 
 
 
 
Table 1: General study characteristics 
 
Author Year Design N= Markers Main findings 
Ceolin28 2018 Retrospective 24 Global DNA 
methylation levels 
Higher global DNA methylation in sMTC than hMTC, but no correlation with tumour characteristics 
and clinical outcome 
Aubert24 2018 Retrospective 54 Tumour miR-183 
and miR-21 
expression 
Both miR-21 and miR-183 were associated with lymph node involvement, and miR-21 was identified 
as an independent prognostic factor for lymph node involvement.  
 
Romeo9 2018 Prospective 33 Circulating miR-375 Circulating miR-375 levels were able to distinguish between patients with persistent sMTC and those 
in remission. Distant metastasis was higher and overall survival lower in those with higher levels of 
circulating miR-375. 
Cote10 2017 Retrospective  75 Circulating RET 
M918T 
Circulating RET M918T mutated DNA found in 32% of those with the mutation identified in tissue 
biopsy, and strongly correlated with worse overall survival 
Cavedon21 2017 Retrospective  107 Somatic miR-224 
and RAS  
Positive association between miR-224 and RAS. miR-224 was a positive prognostic marker, inversely 
associated with persistent/progressive disease, calcitonin and disease-related death.  
Galuppini25 2017 Retrospective 104 Tumour miR-375 
expression 
miR-375 expression was associated with tumour size, capsule invasion, lymph node involvement and 
stage at diagnosis, although 26 hMTCs were included in the analysis. 
Romei11 2016 Retrospective  70 Somatic RET Positive correlation between poor prognosis and number of somatic RET mutations identified 
Grubbs23 2016 Retrospective  62 Somatic CDKN2C 
copy number loss 
Increased distant metastasis and reduced overall survival in the presence of Somatic CDKN2C copy 
number loss 
Wang29 2016 Retrospective  39 Somatic TERT 
promoter 
methylation 
Lower overall and disease-specific survival in patients with high TERT promoter methylation 
Simbolo12 2014 Retrospective 20 Somatic RET and 
RAS mutations 
No significant association between somatic mutation and clinical outcomes.  
Lyra30 2014 Retrospective 77 Tumour mTOR 
activation 
Increased mTOR activation (as measured by p-S6 expression) associated with lymph node metastasis 
and invasive tumours, although 10 hMTCs were included in the analysis. 
Ciampi13 2013 Retrospective 175 Somatic RET and 
RAS mutations 
Non-significant correlation between somatic RAS mutations and better outcomes. Somatic RET 
mutations predicted worse biochemical cure rates and higher disease progression rates than both RAS 
negative RET negative and RAS positive RET negative cases.  
Mian26 2012 Retrospective 34 Somatic expression 
of miR-21, miR-127, 
miR-154, miR-224, 
miR-323, miR-370, 
miR-9*, miR-183, 
and miR-375 
miR-224 expression levels inversely associated with nodal metastasis and disease stage, and 
positively associated with biochemical cure. 
Romei14 2012 Retrospective 160 Somatic RET M918T 
mutations 
Somatic RET M918T mutations were associated with larger primary tumours.  
Wells8 2012 RCT 298 Somatic RET M918T  Phase III clinical trial on vandetanib, which found a higher response rate to the drug in sMTC 
patients with the somatic RET M918T mutation.  
Abraham27 2011 Retrospective 12 Tumour miR-183 
and miR-375 
expression 
Increased expression of miR-183 and miR-375 correlated with lateral compartment nodal metastasis, 
distant metastasis and mortality, although 7 hMTCs were included in the analysis.  
Mian15 2011 Retrospective 60 Somatic RET and Ki-
67 expression 
Both somatic RET and tumour Ki-67 expression correlated positively with tumour size, nodal 
metastasis, distant metastasis and low overall survival.  
Moura22 2011 Retrospective 65 Somatic RET and 
RAS mutations 
No statistically significant differences in clinicopathological parameters between RAS positive and 
RAS negative cases 
Moura16 2009 Retrospective 51 Somatic RET 
mutations 
Tumours with somatic RET mutations affecting exons 15 and 16 were associated with higher rates of 
lymph node metastasis, redisual disease, advanced disease and persistently raised calcitonin 
compared with tumours harbouring other RET mutations or no RET mutation.  
Dvorakova17 2008 Retrospective 48 Somatic RET 
mutation 
Somatic RET mutations were associated with more advanced stage at presentation, but not with other 
clinical and pathological characteristics. 
Elisei18 2008 Retrospective 100 Somatic RET 
mutation 
Somatic RET correlated with advanced stage a presentation and worse overall survival (10 years 
follow-up). M918T somatic RET mutations correlated with larger tumours, nodal metastases and 
distant metastases. 
Schilling19 2001 Retrospective 34 Somatic RET 
mutation 
Somatic M918T RET mutations were associated with higher rates of distant metastasis, lower 
metastasis-free survival and lower overall survival. 
Romei20 1996 Retrospective 18 Somatic RET 
mutations 
Somatic RET mutations were associated with higher rates of post-treatment recurrence or high serum 
calcitonin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Summary of prognostic biomarkers in sporadic medullary thyroid carcinoma (WT=wild-type; DMFS = distant metastasis free 
survival; DFS = disease free survival; OS = overall survival; NS = not statistically significant) 
 
 
Biomarker 
Outcome  
References Stage at 
presentation 
Calcitonin at 
presentation 
Lymph node 
metastasis 
Distant 
metastasis 
Persistent 
disease at 
follow up 
DFS OS 
Somatic RET M918T 
or A883F versus RET 
wild-type 
   
 
 
 
 
 
  
 
Moura 200916 
Schilling 200119 
Somatic RET mutation 
versus RET wild-type 
 
 
  
 
 
  
 
  
 
Elisei 200818 
Dvorakova 200817 
Ciampi 201313 
Tumour miR-375 
over-expression 
 
  
 
 
 
 
 
   
 
Abraham 201127 
Galuppini 201725 
Tumour miR-183 
over-expression 
 
 
 
  
 
 
 
   
 
 
Abraham 201127 
Tumour miR-21 over-
expression 
 
 
 
 
 
 
 
     
Aubert 201822 
Tumour miR-224 
under-expression 
 
 
 
 
 
   
 
 
 
  
Cavedon 201721 
Tumour TERT 
hypermethylation 
 
      
 
 
 
 
Wang 201629 
Somatic CDKN2C 
copy number loss 
 
       
 
 
Grubbs 201623 
Somatic RAS mutation 
versus RAS wild-type 
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Figure Legends 
 
Figure 1: Preferred Reporting Items for Systematic reviews and Meta-Analyses 2009 
(PRISMA) diagram 
 
Figure 2: Schematic representation of selected downstream signalling pathways activated by 
RET, with sites of possible novel therapy action. Vandetanib and cabozantinib directly inhibit 
RET. Tipifarnib is a farnesyltransferase inhibitor which ultimately inactivates RAS. Sorafenib 
is a tyrosine kinase inhibitor, which deactivates the RAS/RAF/MEK/ERK pathway. 
Everolimus binds to a protein receptor, which directly inhibits mTOR. (PI3K = 
phosphoinositide 3-kinase; AKT = protein kinase B; mTOR = mammalian target of 
rapamycin; RAF = rapidly accelerated fibrosarcoma kinase; MEK = MAPK/ERK kinase; ERK 
= Extracellular signal kinase) 
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 Appendix	1:	Search	Log		
#	 Searches	 Results	 Type	
1	 Medullary	carcinoma.sh	 2473	 Advanced	
2	 Medullary	carcinoma.af	 13184	 Advanced	
3	 Sporadic	medullary	thyroid	cancer.ti	 51	 Advanced	
4	 Sporadic	medullary	thyroid	carcinoma.ti	 224	 Advanced	
5	 1	or	2	or	3	or	4	 13315	 Advanced	
6	 Epigenetics.sh	 63624	 Advanced	
7	 Molecular	genetics.sh	 147654	 Advanced	
8	 RET.ti	 5511	 Advanced	
9	 RAS.ti	 35313	 Advanced	
10	 microRNAs.sh	 64738	 Advanced	
11	 miR.ti	 54590	 Advanced	
12	 6	or	7	or	8	or	9	or	10	or	11	 352177	 Advanced	
13	 5	and	12	 1036	 Advanced	
14	 Limit	13	to	English	language	 966	 Advanced	
15	 Limit	14	to	human	 879	 Advanced	
16	 Limit	15	to	yr=	‘1994-current’	 868	 Advanced	
17	 Limit	16	to	humans	 868	 Advanced	
18	 Remove	duplicates	from	17	 788	 Advanced	
19	 From	17	keep	3,	8,	11,	13,	19-20,	63-64…	 34	 Advanced	
20	 From	18	keep	3,	8,	10-11,	13,	19-20,	30…	 40	 Advanced		
 
 
 
 
 
 
 
 
 
Appendix 2:  Modified Newcastle Ottawa scale for assessing risk of bias 
 
 
1. Patient selection Score 
Was case definition adequate?  
Was selection consecutive?  
Were community controls used?  
Were controls defined?  
Were controls comparable to cases?  
2. Data collection  
Was outcome assessed by record linkage?  
Was follow-up long enough for events to occur?  
Were all subjects accounted for in follow-up?  
Total  
 
